Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sonitus Continues Climb Toward Reimbursement With Series D

This article was originally published in Start Up

Executive Summary

Early last year, Sonitus Medical obtained 510(k) notification for its non-surgical hearing assistance device to be used in patients with single-sided deafness. The culmination of five years of work, the FDA clearance positioned Sonitus to compete in, and company officials hope ultimately to expand, the $100 million market for devices for conductive hearing loss. But to do that effectively, the company still needs to convince Centers for Medicaid and Medicare Services and private payors.

You may also be interested in...



US FDA Complete Response Letter Rates Vary With Sponsor Size

Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?

Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals

Commissioner expresses concern about agency lawyers leaving and then representing US FDA’s opponents in court. Also, as lawsuits about abortion pill continue, Kaiser Family Foundation finds the public trusts FDA more than the judiciary on determining products’ safety and effectiveness.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel